| 1 |
29022281 | Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma: A Contemporary Systematic Review and Meta-Analysis. | 2017 Dec |
1 |
| 2 |
22674435 | Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. | 2013 Feb |
1 |
| 3 |
20429035 | Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases. | 2010 Nov |
1 |
| 4 |
18066703 | Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. | 2007 Dec |
1 |
| 5 |
16462850 | Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. | 2006 Feb |
1 |
| 6 |
16025434 | The nitrogen mustard melphalan activates mitogen-activated phosphorylated kinases (MAPK), nuclear factor-kappaB and inflammatory response in lung epithelial cells. | 2005 Jul-Aug |
1 |
| 7 |
16178815 | Tumor necrosis factor: how to make a killer molecule tumor-specific? | 2005 Sep |
1 |
| 8 |
15053862 | Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides. | 2004 Apr |
1 |
| 9 |
12388254 | TNF-alpha downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model. | 2003 Jan |
1 |
| 10 |
12850194 | Current uses of isolated limb perfusion in the clinic and a model system for new strategies. | 2003 Jul |
2 |
| 11 |
16767914 | Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study. | 2003 Dec |
3 |
| 12 |
11986187 | Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. | 2002 May |
1 |
| 13 |
11309322 | Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. | 2001 Apr |
1 |
| 14 |
11389822 | Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. | 2001 Jul |
1 |
| 15 |
11417986 | Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. | 2001 Jun |
2 |
| 16 |
10100597 | A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia. | 1999 |
1 |
| 17 |
9621525 | Systemic or regional chemotherapy: does it matter and should surgeons be involved? | 1998 Apr |
2 |
| 18 |
9809994 | Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. | 1998 Nov 1 |
1 |
| 19 |
9166943 | Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. | 1997 |
2 |